264 related articles for article (PubMed ID: 33903734)
1. Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.
Han H; Lee HH; Choi K; Moon YJ; Heo JE; Ham WS; Jang WS; Rha KH; Cho NH; Giancotti FG; Choi YD
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1080-1092. PubMed ID: 33903734
[TBL] [Abstract][Full Text] [Related]
2. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
[TBL] [Abstract][Full Text] [Related]
3. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
4. A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Weiner AB; Liu Y; Hakansson A; Zhao X; Proudfoot JA; Ho J; Zhang JH; Li EV; Karnes RJ; Den RB; Kishan AU; Reiter RE; Hamid AA; Ross AE; Tran PT; Davicioni E; Spratt DE; Attard G; Lotan TL; Lee Kiang Chua M; Sweeney CJ; Schaeffer EM
Cancer; 2023 Jul; 129(14):2169-2178. PubMed ID: 37060201
[TBL] [Abstract][Full Text] [Related]
5. Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.
Lin HM; Castillo L; Mahon KL; Chiam K; Lee BY; Nguyen Q; Boyer MJ; Stockler MR; Pavlakis N; Marx G; Mallesara G; Gurney H; Clark SJ; Swarbrick A; Daly RJ; Horvath LG
Br J Cancer; 2014 May; 110(10):2462-71. PubMed ID: 24714754
[TBL] [Abstract][Full Text] [Related]
6. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
7. Metronomic Administration of Topotecan Alone and in Combination with Docetaxel Inhibits Epithelial-mesenchymal Transition in Aggressive Variant Prostate Cancers.
Mitra Ghosh T; Mazumder S; Davis J; Yadav J; Akinpelu A; Alnaim A; Kumar H; Waliagha R; Church Bird AE; Rais-Bahrami S; Bird RC; Mistriotis P; Mishra A; Yates CC; Mitra AK; Arnold RD
Cancer Res Commun; 2023 Jul; 3(7):1286-1311. PubMed ID: 37476073
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.
Babasaki T; Sentani K; Sekino Y; Kobayashi G; Thang Pham Q; Katsuya N; Akabane S; Taniyama D; Hayashi T; Shiota M; Oue N; Teishima J; Matsubara A; Yasui W
Cancer Med; 2021 Aug; 10(16):5574-5588. PubMed ID: 34240817
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.
Bryce AH; Chen YH; Liu G; Carducci MA; Jarrard DM; Garcia JA; Dreicer R; Hussain M; Eisenberger MA; Plimack ER; Vogelzang NJ; DiPaola RS; Harshman L; Sweeney CJ
Eur Urol Oncol; 2020 Dec; 3(6):717-724. PubMed ID: 32807727
[TBL] [Abstract][Full Text] [Related]
11. Serum TPS, PSA, and PAP values in relapsing stage D2 adenocarcinoma of the prostate.
Kraljić I; Kovacić K; Tarle M
Urol Res; 1994; 22(5):329-32. PubMed ID: 7533445
[TBL] [Abstract][Full Text] [Related]
12. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy combined with androgen-deprivation therapy in high-volume metastatic hormone sensitive prostate cancer: a short-term efficacy and safety analysis].
Xu PH; Shen YJ; Xiao WJ; Lin GW; Qin XJ; Zhu Y; Dai B; Ye DW
Zhonghua Wai Ke Za Zhi; 2019 Jun; 57(6):418-421. PubMed ID: 31142065
[No Abstract] [Full Text] [Related]
14. PSA time to nadir as a prognostic factor of first-line docetaxel treatment in castration-resistant prostate cancer: evidence from patients in Northwestern China.
Wu KJ; Pei XQ; Tian G; Wu DP; Fan JH; Jiang YM; He DL
Asian J Androl; 2018; 20(2):173-177. PubMed ID: 28905815
[TBL] [Abstract][Full Text] [Related]
15. Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers.
Aparicio AM; Shen L; Tapia EL; Lu JF; Chen HC; Zhang J; Wu G; Wang X; Troncoso P; Corn P; Thompson TC; Broom B; Baggerly K; Maity SN; Logothetis CJ
Clin Cancer Res; 2016 Mar; 22(6):1520-30. PubMed ID: 26546618
[TBL] [Abstract][Full Text] [Related]
16. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
Atkins KM; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
Cancer; 2018 Apr; 124(7):1383-1390. PubMed ID: 29266181
[TBL] [Abstract][Full Text] [Related]
17. Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-variant Prostate Cancer.
Wang R; Xu Q; Guo H; Yang G; Zhang J; Wang H; Xu T; Guo C; Yuan J; He Y; Zhang X; Fu H; Xu G; Zhao B; Xie J; Zhao T; Huang L; Zhang J; Peng B; Yao X; Yang B
Cancer Res Commun; 2023 Nov; 3(11):2221-2232. PubMed ID: 37877742
[TBL] [Abstract][Full Text] [Related]
18. Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer.
Malihi PD; Graf RP; Rodriguez A; Ramesh N; Lee J; Sutton R; Jiles R; Ruiz Velasco C; Sei E; Kolatkar A; Logothetis C; Navin NE; Corn P; Aparicio AM; Dittamore R; Hicks J; Kuhn P; Zurita AJ
Clin Cancer Res; 2020 Aug; 26(15):4143-4153. PubMed ID: 32341031
[TBL] [Abstract][Full Text] [Related]
19. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer.
Aggarwal R; Romero GR; Friedl V; Weinstein A; Foye A; Huang J; Feng F; Stuart JM; Small EJ
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):81-87. PubMed ID: 32286548
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease.
Kamoun A; Cancel-Tassin G; Fromont G; Elarouci N; Armenoult L; Ayadi M; Irani J; Leroy X; Villers A; Fournier G; Doucet L; Boyault S; Brureau L; Multigner L; Diedhiou A; Roupret M; Compérat E; Blanchet P; de Reyniès A; Cussenot O
Ann Oncol; 2018 Aug; 29(8):1814-1821. PubMed ID: 29945238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]